Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.32 |
| ▸ | DRD4 | P21917 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1648940 | 0.82 | METAP2 (0.39) | — | |
| SCHEMBL1648202 | 0.81 | SIGMAR1 (0.34) | MEN1HTR1AADRA2ACYP2D6DRD2 | |
| SCHEMBL1650155 | 0.79 | MEN1 (0.36) | MEN1HTR1AADRA2ACYP2D6DRD2 | |
| SCHEMBL1649232 | 0.78 | SIGMAR1 (0.38) | MEN1HTR1AADRA2ACYP2D6DRD2 | |
| SCHEMBL16863821 | 0.77 | MEN1 (0.33) | MEN1HTR1AADRA2ACYP2D6DRD2 | |
| SCHEMBL14725788 | 0.74 | CA1 (0.38) | MEN1HTR1AADRA2ACYP2D6DRD2 | |
| SCHEMBL1648942 | 0.73 | SIGMAR1 (0.38) | MEN1HTR1AADRA2ACYP2D6DRD2 | |
| SCHEMBL1648543 | 0.73 | CA12 (0.37) | MEN1HTR1AADRA2ACYP2D6DRD2 | |
| SCHEMBL1648540 | 0.73 | MEN1 (0.36) | MEN1HTR1AADRA2ACYP2D6DRD2 | |
| SCHEMBL1648538 | 0.73 | CA1 (0.37) | MEN1HTR1AADRA2ACYP2D6DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2486004-B1 | SULPHONE COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY | ZAFGEN INC (US) | 2017-05-03 | — | — | EP | disclosed |
| US-20160051531-A1 | SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN INC (US) | 2016-02-25 | — | — | US | disclosed |
| US-9067905-B2 | Sulphone compounds and methods of making and using same | ZAFGEN, INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-20130053364-A1 | Sulphone Compounds and Methods of Making and Using Same | ZAFGEN, INC. | 2013-02-28 | — | — | US | disclosed |
| US-20130053364-A1 | Sulphone Compounds and Methods of Making and Using Same | ZAFGEN, INC. | 2013-02-28 | — | — | US | disclosed |
| EP-2486004-A2 | SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME | Zafgen Corporation (US) | 2012-08-15 | — | — | EP | disclosed |
| WO-2011044506-A2 | SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN CORPORATION (US) | 2011-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160051531-A1 | SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME | METAP2, DNPEP, STS | MEN1 1603/4885HTR1A 1817/4885ADRA2A 3548/4885 |
| US-20130053364-A1 | Sulphone Compounds and Methods of Making and Using Same | METAP2, DNPEP, STS | MEN1 1603/4885HTR1A 1817/4885ADRA2A 3548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.